OTCMKTS:CRXLY - Crucell Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Crucell NV is a Netherlands-based biopharmaceutical company. The Company is focused on developing, producing and marketing products that combat infectious diseases. The Company's product candidates include flu-mAb, an antibody product effective against a range of influenza virus strains, tuberculosis and malaria vaccines, as well as a rabies monoclonal antibody combination, all produced on its PER.C6 human cell-line technology. It focuses on the paediatric, travel and endemic, and respiratory fields. Its core product portfolio includes Quinvaxem, a liquid pentavalent vaccine against five important childhood diseases; Hepavax-Gene, a hepatitis B vaccine; Epaxal, an aluminum-free hepatitis A vaccine; Vivotif and Dukoral, oral vaccines against typhoid and cholera; and Inflexal V, a virosomal adjuvanted vaccine against influenza. It has offices in the Netherlands, China, Indonesia, Italy, Korea, Malaysia, Spain, Sweden, Switzerland, the United Kingdom, the United States and Vietnam.

Receive CRXLY News and Ratings via Email

Sign-up to receive the latest news and ratings for CRXLY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolOTCMKTS:CRXLY
Previous SymbolNASDAQ:CRXL
CUSIPN/A
CIKN/A
WebN/A
Phone+31-71-5199100

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Crucell (OTCMKTS:CRXLY) Frequently Asked Questions

What is Crucell's stock symbol?

Crucell trades on the OTCMKTS under the ticker symbol "CRXLY."

Has Crucell been receiving favorable news coverage?

News headlines about CRXLY stock have been trending positive on Tuesday, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Crucell earned a news impact score of 2.7 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days.

How do I buy shares of Crucell?

Shares of CRXLY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Crucell?

Crucell's mailing address is Archimedesweg 4, LEIDEN, 2333CN, Netherlands. The biopharmaceutical company can be reached via phone at +31-71-5199100.


MarketBeat Community Rating for Crucell (OTCMKTS CRXLY)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  53 (Vote Outperform)
Underperform Votes:  48 (Vote Underperform)
Total Votes:  101
MarketBeat's community ratings are surveys of what our community members think about Crucell and other stocks. Vote "Outperform" if you believe CRXLY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CRXLY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/23/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel